Skip to main content
. 2020 Oct 14;46:101102. doi: 10.1016/j.molmet.2020.101102

Figure 3.

Figure 3

Optical appearance and properties of pen injection devices for approved GLP-1 receptor agonists (as mono substances or fixed-dose combinations with basal insulin). Modified from Nauck and Meier 2019 [20]. ∗Thorough shaking was necessary to evenly resuspend the active ingredient. The ease of use was estimated semi-quantitatively based on informal feedback from patients using these pen injection devices.